Press Releases Archives - Page 37 of 103 - Lupin

BSE 2287.30 NSE 2270.60

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2287.30 NSE 2270.60

Lupin Receives Tentative U.S. FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR

Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the United States

Lupin Receives U.S. FDA Approval for Sevelamer Hydrochloride Tablets

Lupin receives UK marketing authorization for Luforbec® 100/6 µg pMDI, first branded generic alternative to Fostair® 100/6 µg pMDI for treatment of Asthma & COPD

Lupin donates Oxygen generation plants in Maharashtra, Madhya Pradesh & Gujarat to aid COVID-19 relief efforts

Lupin Launches Authorized Generic Version of Brovana® in the United States

Lupin announces U.S. FDA acceptance for Pegfilgrastim Biosimilar application

Lupin Announces Achievement of Key Milestones for its Clinical Stage MEK Inhibitor Compound

Lupin Q4 FY2021 Results

Lupin enters into Voluntary Licensing Agreement with Lilly to Expand Access for COVID-19 Treatment in India

1 2 … 36 37 38 … 102 103

Search

Hit enter to search or ESC to close